Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative

This page shows the latest neurodegenerative news and features for those working in and with pharma, biotech and healthcare.

Celgene bulks up pipeline again with $2.1bn Prothena deal

Celgene bulks up pipeline again with $2.1bn Prothena deal

Its latest deal gives it a preclinical-stage collaboration focused on targets with potential in neurodegenerative diseases including Alzheimer’s. ... Our collaboration leverages each company’s core expertise in protein homeostasis and protein

Latest news

More from news
Approximately 7 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    These deals were mainly early stage deals in the areas of gastroenterology, neurodegenerative diseases and an $830m ($40m upfront) deal with Mersana for rights outside North America to a phase 1

  • Deal Watch December 2016 Deal Watch December 2016

    320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases.

  • Deal Watch November 2016 Deal Watch November 2016

    equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose combinations for Alzheimer's and other neurodegenerative diseases inc CPC-201 (donepezil).

  • Deal Watch February 2016 Deal Watch February 2016

    The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Asceneuron appoints chief medical officer. Novartis’ Michael Ryan joins the neurodegenerative diseases specialist. ... He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    Prof De Strooper is currently a professor of molecular medicine at the University of Leuven and leads its laboratory for the research of neurodegenerative diseases.

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: “ Dr Isacson's deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer's and

  • Minoyrx Therapeutics appoints chief medical officer Minoyrx Therapeutics appoints chief medical officer

    He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders. ... Prior to this, Dr Meya was

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai's Cheung said: "With her deep expertise in the commercial development of in-line and pipeline compounds, and extensive knowledge of Alzheimer's disease and other neurodegenerative disease states, Beyhan

More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest from PMHub

  • Alzheimer's and Brain Awareness Month

    AD is a neurodegenerative disease, meaning that its symptoms are generally mild at the start, but become progressively worse over time, eventually interfering with the everyday life of those affected.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics